In Tg-AD rats, Timapiprant administered orally in rodent chow significantly mitigated Aβ plaque load in the hippocampal DG hilar subregion. In the laser-induced CNV mouse model, subcutaneous Timapiprant (OC000459) produced significantly smaller CNV sizes than vehicle. In mice undergoing caerulein intervention, daily i.p. Timapiprant (OC000459) treatment resulted in significantly less fibrotic tissue than vehicle. In Tg-AD rats, oral Timapiprant also alleviated neuronal loss in the GCL subregion. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Reduced hippocampal amyloid plaque burden in Tg-AD rats
Animal study · 11-mo-old Tg-AD [1]
Tg-AD rats received Timapiprant orally in rodent chow at 15 mg/kg body weight/day/rat for 4 mo. Treatment significantly mitigated Aβ plaque load in the hippocampal DG hilar subregion compared with untreated Tg-AD rats.
Conditions shared by the study groups
- Route
- administered orally in rodent chow
- Treatment course
- At 7 mo; for 4 mo
- Vehicle
- rodent chow (Research Diets Inc.)
- Timapiprant 15 mg/kg body weight/day/rat
- Model: 11-mo-old Tg-AD
Methods and source locations
Compound reported in the paper: Timapiprant
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Timapiprant improves spatial learning and mitigates plaque burden, neuronal loss, and microgliosis in Tg-AD rats (S98, S103); Materials and Methods > Experimental design (S118, S119); Figure 10. legend (S286)
Aβ plaque burden in the hippocampal DG hilar subregion: Aβ plaque burden in the hippocampal DG hilar subregion; comparator: Tg-AD non-treated (TGNT, n = 9) male rats — Results > Timapiprant improves spatial learning and mitigates plaque burden, neuronal loss, and microgliosis in Tg-AD rats (S103); Materials and Methods > Experimental design (S119)
Timapiprant 15 mg/kg body weight/day/rat · Results > Timapiprant improves spatial learning and mitigates plaque burden, neuronal loss, and microgliosis in Tg-AD rats (S103); Materials and Methods > Experimental design (S118, S119)
Reduced lesion size in laser-induced choroidal neovascularization
Animal study · Male C57BL/6 mice; laser-induced CNV model; n = 79 spots of 16 eyes [2]
Male mice with laser-induced CNV received subcutaneous Timapiprant (OC000459) at 2 mg/mL. CNV sizes were significantly smaller than in the vehicle group at 7 days after laser photocoagulation.
Conditions shared by the study groups
- Route
- subcutaneous administration
- Treatment course
- from 1 day before CNV induction; for 7 days
- Vehicle
- 1:100 DMSO in PBS
- Timapiprant 2 mg/mL; 1.2 mg/day/kg
- Model: Male C57BL/6 mice; laser-induced CNV model; n = 79 spots of 16 eyes
Methods and source locations
Compound reported in the paper: Timapiprant; Compound label in the paper: OC000459
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Animals (S1); Methods > Induction of CNV (S5); Methods > Measurement of CNV Size and Immunohistochemistry (S9); Methods > DP2 Antagonist Administration (S14, S15, S16); Results (S59, S60); Figure 2. legend (S84, S85)
The CNV sizes; at 7 days after laser photocoagulation: The CNV sizes; at 7 days after laser photocoagulation; comparator: vehicle groups (n = 74 spots of 17 eyes) — Results (S59, S60); Figure 2. legend (S84)
Timapiprant 2 mg/mL; 1.2 mg/day/kg · Methods > DP2 Antagonist Administration (S16); Results (S59, S60); Figure 2. legend (S85)
Reduced fibrotic tissue in caerulein-treated mice
Animal study · C57Bl/6 mice; Veh. n = 8/OC n = 8 [3]
In the caerulein intervention model, mice received Timapiprant (OC000459) at 30 µg i.p. once daily. Treated mice had significantly less fibrotic tissue than vehicle-treated mice.
Conditions shared by the study groups
- Route
- i.p.
- Treatment course
- once daily
- Vehicle
- 0.625% DMSO
- Timapiprant 30 µg
- Model: C57Bl/6 mice; Veh. n = 8/OC n = 8
Methods and source locations
Compound reported in the paper: Timapiprant; Compound label in the paper: OC000459
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Animal model (S163, S169); Methods > Histology, immunohistochemistry, and immunofluorescence (S198); Fig. 4 legend (S259, S260)
Quantification by pattern quant software: Quantification by pattern quant software; comparator: vehicle (0.625% DMSO) — Fig. 4 legend (S260)
Timapiprant 30 µg · Methods > Animal model (S169); Fig. 4 legend (S260)
Alleviated neuronal loss in Tg-AD rats
Animal study · 11-mo-old Tg-AD [1]
Tg-AD rats received Timapiprant orally in rodent chow at 15 mg/kg body weight/day/rat for 4 mo. Treatment alleviated neuronal loss in the GCL subregion.
Conditions shared by the study groups
- Route
- administered orally in rodent chow
- Treatment course
- At 7 mo; for 4 mo
- Vehicle
- rodent chow (Research Diets Inc.)
- Timapiprant 15 mg/kg body weight/day/rat
- Model: 11-mo-old Tg-AD
Methods and source locations
Compound reported in the paper: Timapiprant
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Timapiprant improves spatial learning and mitigates plaque burden, neuronal loss, and microgliosis in Tg-AD rats (S98, S104); Materials and Methods > Experimental design (S118, S119); Figure 10. legend (S286)
neuronal loss in the GCL subregion: neuronal loss in the GCL subregion; comparator: Tg-AD non-treated (TGNT, n = 9) male rats — Results > Timapiprant improves spatial learning and mitigates plaque burden, neuronal loss, and microgliosis in Tg-AD rats (S104); Materials and Methods > Experimental design (S119)
Timapiprant 15 mg/kg body weight/day/rat · Results > Timapiprant improves spatial learning and mitigates plaque burden, neuronal loss, and microgliosis in Tg-AD rats (S104); Materials and Methods > Experimental design (S118, S119)